Globus Medical (GMED) Competitors $62.54 +2.04 (+3.38%) Closing price 03:59 PM EasternExtended Trading$62.54 -0.01 (-0.01%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GMED vs. DXCM, STE, PODD, HOLX, BAX, MASI, TFX, ITGR, ATEC, and ATRCShould you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Masimo (MASI), Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), and AtriCure (ATRC). These companies are all part of the "health care equipment" industry. Globus Medical vs. Its Competitors DexCom STERIS Insulet Hologic Baxter International Masimo Teleflex Integer Alphatec AtriCure Globus Medical (NYSE:GMED) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk. Do institutionals & insiders hold more shares of GMED or DXCM? 95.2% of Globus Medical shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 18.5% of Globus Medical shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, GMED or DXCM? Globus Medical has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Is GMED or DXCM more profitable? Globus Medical has a net margin of 13.58% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Globus Medical's return on equity.Company Net Margins Return on Equity Return on Assets Globus Medical13.58% 10.65% 8.86% DexCom 13.29%30.41%10.08% Which has preferable valuation & earnings, GMED or DXCM? DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobus Medical$2.63B3.22$102.98M$2.6024.06DexCom$4.03B8.00$576.20M$1.4457.13 Do analysts prefer GMED or DXCM? Globus Medical currently has a consensus price target of $87.64, suggesting a potential upside of 40.12%. DexCom has a consensus price target of $99.90, suggesting a potential upside of 21.44%. Given Globus Medical's higher probable upside, equities research analysts plainly believe Globus Medical is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Globus Medical 0 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.62DexCom 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.96 Does the media favor GMED or DXCM? In the previous week, DexCom had 20 more articles in the media than Globus Medical. MarketBeat recorded 33 mentions for DexCom and 13 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.33 beat DexCom's score of 1.28 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 24 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDexCom beats Globus Medical on 12 of the 17 factors compared between the two stocks. Get Globus Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMED vs. The Competition Export to ExcelMetricGlobus MedicalMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$8.45B$7.05B$5.82B$21.16BDividend YieldN/A1.30%3.84%3.59%P/E Ratio24.0627.1631.1529.15Price / Sales3.22145.24475.1554.92Price / Cash9.1221.6837.1523.84Price / Book1.976.869.115.45Net Income$102.98M$176.42M$3.26B$992.10M7 Day Performance3.16%0.58%2.11%2.62%1 Month Performance17.85%-0.45%5.12%2.51%1 Year Performance-10.24%13.07%31.25%12.94% Globus Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMEDGlobus Medical4.9471 of 5 stars$62.54+3.4%$87.64+40.1%-13.1%$8.45B$2.63B24.065,300DXCMDexCom4.8505 of 5 stars$77.85-1.3%$99.89+28.3%+10.1%$30.93B$4.03B54.0610,300Positive NewsAnalyst ForecastSTESTERIS4.2384 of 5 stars$241.66-0.5%$273.50+13.2%+5.5%$23.89B$5.46B37.0117,787Positive NewsInsider TradePODDInsulet4.3714 of 5 stars$304.84-0.7%$330.71+8.5%+76.5%$21.61B$2.07B92.663,900Positive NewsAnalyst ForecastHOLXHologic4.8784 of 5 stars$67.99-0.1%$77.83+14.5%-16.1%$15.14B$4.03B28.217,063Positive NewsAnalyst RevisionBAXBaxter International4.7261 of 5 stars$23.47-0.9%$30.11+28.3%-34.1%$12.17B$10.64B-78.2338,000MASIMasimo4.4543 of 5 stars$147.37+1.8%$193.60+31.4%+16.9%$7.86B$2.09B-17.305,600News CoverageTFXTeleflex4.5794 of 5 stars$115.96-2.1%$141.57+22.1%-47.7%$5.23B$3.05B27.2814,100Positive NewsITGRInteger4.1918 of 5 stars$105.44-0.9%$140.25+33.0%-13.2%$3.73B$1.72B46.4511,000Positive NewsATECAlphatec4.0232 of 5 stars$15.32+2.3%$18.50+20.8%+180.5%$2.22B$611.56M-13.56700Insider TradeATRCAtriCure3.1545 of 5 stars$35.49+0.5%$50.89+43.4%+48.9%$1.75B$465.31M-46.091,300News CoverageInsider TradeShort Interest ↑ Related Companies and Tools Related Companies DexCom Alternatives STERIS Alternatives Insulet Alternatives Hologic Alternatives Baxter International Alternatives Masimo Alternatives Teleflex Alternatives Integer Alternatives Alphatec Alternatives AtriCure Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GMED) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Globus Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access